Are We Sacrificing Good for Perfect in Clinical Outcome Assessment?

Are We Sacrificing Good for Perfect in Clinical Outcome Assessment?

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy Officer at Clinical Outcome Solutions, to discuss whether the field of clinical outcome assessment has started sacrificing “good for perfect.” Together, they explore the role of regulatory guidance and clinical development timelines, specifically the role of measurement science in already tight development timelines, when to modify a legacy instrument versus build something new, and why getting measurement scientists involved early is the key to a successful COA strategy.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(30)

The "Frankenstein Instrument" Problem Why Some PRO Measures Don't Fit Today's Patients

The "Frankenstein Instrument" Problem Why Some PRO Measures Don't Fit Today's Patients

Are the COA Instruments we've relied on for decades still measuring what matters to patients today? In this episode, Mark Wade sits down with Kathrin Fischer PhD, Patient-Centered Outcome Strategy Lea...

14 Sep 23min

Why eConsent Still Isn’t Standard in Clinical Trials—and What Could Change That

Why eConsent Still Isn’t Standard in Clinical Trials—and What Could Change That

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Edwin Cohen, Principal Consultant at C&Flow, to talk about eConsent adoption in clinic...

4 Aug 19min

Nothing Remains the Same: Why Measures Have to Evolve

Nothing Remains the Same: Why Measures Have to Evolve

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with RJ Wirth, CEO and Consulting Psychometrician at Vector Psychometric Group, to talk abo...

21 Jul 23min

The Missing Link: Why Study Design Makes or Breaks a Clinical Trial

The Missing Link: Why Study Design Makes or Breaks a Clinical Trial

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Farrell Healion, Founder and Principal Consultant at OptiTrial, to explore why study d...

9 Jun 22min

More Than an Aspiration: Building a Patient-Centric Evidence Strategy That Lasts

More Than an Aspiration: Building a Patient-Centric Evidence Strategy That Lasts

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Lina Eliasson PhD CPsycho, Founding Partner at Sprout Health Solutions, to discuss how...

23 Mar 23min

Building Fit-for-Purpose PRO Instruments: Focused Modern Measures Over General Instruments

Building Fit-for-Purpose PRO Instruments: Focused Modern Measures Over General Instruments

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader & COA SME at TransPerfect Life Sciences, is joined by Katja Rudell, VP of Patient-Centered Outcomes at Kielo Research, to take a beh...

10 Feb 20min

Meaningful patient involvement in HTA decision making: where do we go from here?

Meaningful patient involvement in HTA decision making: where do we go from here?

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Alice Biggane, Outcomes Innovation and Research Lead at Pfizer UK, to discuss how vari...

7 Okt 202519min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
romkapsel
dekodet-2
sinnsyn
liberal-halvtime
rekommandert
rss-paradigmepodden
forskningno
rss-nysgjerrige-norge
fjellsportpodden
rss-rekommandert
nordnorsk-historie
grunnstoffene
noen-har-snakket-sammen
vett-og-vitenskap-med-gaute-einevoll
tidlose-historier
villmarksliv
rss-bondevennen
rss-overskuddsliv